BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND NTRK3, TRKC, 4916, ENSG00000140538, Q16288, gp145 trkC
36 results:

  • 1. Cost-Efficient Detection of
    Romanko AA; Mulkidjan RS; Tiurin VI; Saitova ES; Preobrazhenskaya EV; Krivosheyeva EA; Mitiushkina NV; Shestakova AD; Belogubova EV; Ivantsov AO; Iyevleva AG; Imyanitov EN
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762506
    [TBL] [Abstract] [Full Text] [Related]  

  • 2.
    Mulkidjan RS; Saitova ES; Preobrazhenskaya EV; Asadulaeva KA; Bubnov MG; Otradnova EA; Terina DM; Shulga SS; Martynenko DE; Semina MV; Belogubova EV; Tiurin VI; Amankwah PS; Martianov AS; Imyanitov EN
    Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686416
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. NTRK fusions in solid tumours: what every pathologist needs to know.
    Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA
    Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Elaboration of NTRK-rearranged colorectal cancer: Integration of immunoreactivity pattern, cytogenetic identity, and rearrangement variant.
    Wu S; Liu Y; Shi X; Zhou W; Zeng X
    Dig Liver Dis; 2023 Dec; 55(12):1757-1764. PubMed ID: 37142453
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.
    Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L
    Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Prevalence of NTRK Fusions in Canadian Solid Tumour cancer Patients.
    Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
    Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas.
    Zhang Z; Pang J; Chen L; Chen J; Li J; Liu H; Wang J; Wu H; Liang Z
    Hum Pathol; 2022 Nov; 129():21-31. PubMed ID: 35977594
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations.
    Principe DR
    Sci Rep; 2022 Jul; 12(1):11490. PubMed ID: 35798829
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric cancer with NTRK Overexpression.
    Sohn SH; Sul HJ; Kim BJ; Kim HS; Zang DY
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008821
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing.
    Wang J; Li R; Li J; Yi Y; Liu X; Chen J; Zhang H; Lu J; Li C; Wu H; Liang Z
    J Transl Med; 2021 Oct; 19(1):433. PubMed ID: 34657620
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
    J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
    Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
    Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
    Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer.
    Chen Z; Huang Z; Luo Y; Zou Q; Bai L; Tang G; Wang X; Cao G; Huang M; Xiang J; Yu H
    J Transl Med; 2021 Feb; 19(1):73. PubMed ID: 33593392
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic cancers.
    Tsang ES; Grisdale CJ; Pleasance E; Topham JT; Mungall K; Reisle C; Choo C; Carreira M; Bowlby R; Karasinska JM; MacMillan D; Williamson LM; Chuah E; Moore RA; Mungall AJ; Zhao Y; Tessier-Cloutier B; Ng T; Sun S; Lim HJ; Schaeffer DF; Renouf DJ; Yip S; Laskin J; Marra MA; Jones SJM; Loree JM
    Clin Cancer Res; 2021 Jan; 27(2):522-531. PubMed ID: 33148671
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Trk receptor tyrosine kinases in metastasis and cancer therapy.
    Regua AT; Doheny D; Arrigo A; Lo HW
    Discov Med; 2019 Oct; 28(154):195-203. PubMed ID: 31928627
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Colonic Adenocarcinomas Harboring NTRK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 16 Cases and Review of the Literature.
    Lasota J; Chłopek M; Lamoureux J; Christiansen J; Kowalik A; Wasąg B; Felisiak-Gołąbek A; Agaimy A; Biernat W; Canzonieri V; Centonze G; Chmielik E; Daum O; Dubová M; Dziuba I; Goertz S; Góźdź S; Guttmejer-Nasierowska A; Haglund C; Hałoń A; Hartmann A; Inaguma S; Iżycka-Świeszewska E; Kaczorowski M; Kita P; Kołos M; Kopczyński J; Michal M; Milione M; Okoń K; Pęksa R; Pyzlak M; Ristimäki A; Ryś J; Szostak B; Szpor J; Szumiło J; Teresiński L; Waloszczyk P; Wejman J; Wesołowski W; Miettinen M
    Am J Surg Pathol; 2020 Feb; 44(2):162-173. PubMed ID: 31567189
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Disparities in minimally invasive surgery for colorectal cancer in Florida.
    Osagiede O; Spaulding AC; Cochuyt JJ; Naessens JM; Merchea A; Kasi PM; Crandall M; Colibaseanu DT
    Am J Surg; 2019 Aug; 218(2):293-301. PubMed ID: 30503514
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.
    Deihimi S; Lev A; Slifker M; Shagisultanova E; Xu Q; Jung K; Vijayvergia N; Ross EA; Xiu J; Swensen J; Gatalica Z; Andrake M; Dunbrack RL; El-Deiry WS
    Oncotarget; 2017 Jun; 8(25):39945-39962. PubMed ID: 28591715
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.